Satu Helske1, Riina Oksjoki1, Ken A Lindstedt1, Jyri Lommi2, Heikki Turto2, Kalervo Werkkala3, Markku Kupari2, Petri T Kovanen4. 1. Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. 2. Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 3. Division of Cardiothoracic Surgery, Helsinki University Central Hospital, Helsinki, Finland. 4. Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. Electronic address: petri.kovanen@wri.fi.
Abstract
OBJECTIVE: To examine the role of the complement system, a source of powerful proinflammatory mediators, in aortic valve stenosis (AS). METHODS AND RESULTS: Stenotic aortic valves (n=24) were obtained at valve replacement surgery, and non-stenotic (n=12) and early sclerotic (n=4) valves at cardiac transplantations. The terminal complement complex C5b-9 was stained by immunohistochemistry. Expression of the anaphylatoxin receptors C3aR and C5aR was studied in the valves by immunohistochemistry and RT-PCR, and in isolated valve myofibroblasts after stimulation with potential AS-accelerating factors (TNF-alpha and cigarette smoke) by RT-PCR. Cultured myofibroblasts were exposed to C3a, and their secretion of proinflammatory cytokines was assessed by ELISA. C5b-9 was found already in early aortic valve lesions, and its deposition was augmented in advanced stenotic valves. In stenotic valves, expression of C3aR mRNA was upregulated (p<0.05) and strong staining of C3aR and C5aR was detected. Myofibroblasts in stenotic, but not in control valves, expressed C3aR, and, in isolated myofibroblasts, TNF-alpha and cigarette smoke induced C3aR mRNA expression (p<0.05 for both). Stimulation of myofibroblasts with C3a resulted in enhanced secretion of MCP-1 (p<0.001), IL-6 (p=0.003), and IL-8 (p=0.03). CONCLUSIONS: In stenotic aortic valves, complement is activated leading to generation of the anaphylatoxins C3a and C5a. Upregulation of C3aR in the valves as a result of inflammation and external risk factors, such as cigarette smoke, leads to an inflammatory response in aortic valve myofibroblasts. Complement activation in stenotic valves emerges as a novel pathogenic component of AS and may serve as a therapeutic target in this disease.
OBJECTIVE: To examine the role of the complement system, a source of powerful proinflammatory mediators, in aortic valve stenosis (AS). METHODS AND RESULTS: Stenotic aortic valves (n=24) were obtained at valve replacement surgery, and non-stenotic (n=12) and early sclerotic (n=4) valves at cardiac transplantations. The terminal complement complex C5b-9 was stained by immunohistochemistry. Expression of the anaphylatoxin receptors C3aR and C5aR was studied in the valves by immunohistochemistry and RT-PCR, and in isolated valve myofibroblasts after stimulation with potential AS-accelerating factors (TNF-alpha and cigarette smoke) by RT-PCR. Cultured myofibroblasts were exposed to C3a, and their secretion of proinflammatory cytokines was assessed by ELISA. C5b-9 was found already in early aortic valve lesions, and its deposition was augmented in advanced stenotic valves. In stenotic valves, expression of C3aR mRNA was upregulated (p<0.05) and strong staining of C3aR and C5aR was detected. Myofibroblasts in stenotic, but not in control valves, expressed C3aR, and, in isolated myofibroblasts, TNF-alpha and cigarette smoke induced C3aR mRNA expression (p<0.05 for both). Stimulation of myofibroblasts with C3a resulted in enhanced secretion of MCP-1 (p<0.001), IL-6 (p=0.003), and IL-8 (p=0.03). CONCLUSIONS: In stenotic aortic valves, complement is activated leading to generation of the anaphylatoxins C3a and C5a. Upregulation of C3aR in the valves as a result of inflammation and external risk factors, such as cigarette smoke, leads to an inflammatory response in aortic valve myofibroblasts. Complement activation in stenotic valves emerges as a novel pathogenic component of AS and may serve as a therapeutic target in this disease.
Authors: Christine E Kamla; Melissa Grigorescu-Vlass; Dietmar Wassilowsky; Michael Fischereder; Christian Hagl; Ulf Schönermarck; Maximilian A Pichlmaier; Sven Peterss; Dominik Jóskowiak Journal: Interact Cardiovasc Thorac Surg Date: 2022-01-18
Authors: Jihyeon Lim; Jennifer T Aguilan; Rani S Sellers; Fnu Nagajyothi; Louis M Weiss; Ruth Hogue Angeletti; Anna E Bortnick Journal: J Mol Histol Date: 2020-08-13 Impact factor: 2.611
Authors: Laura Twardowski; Fei Cheng; Jens Michaelsen; Stefan Winter; Ute Hofmann; Elke Schaeffeler; Simon Müller; Maike Sonnenberg; Kristin Steuer; German Ott; Matthias Schwab; Ulrich F W Franke; Michael Torzewski Journal: J Am Heart Assoc Date: 2015-10-16 Impact factor: 5.501